Therapies
The Science
About us
Investors
News

Hit enter to search or ESC to close

Dr David Stamler’s Biotech Showcase Presentation

January 7, 2019 Kerry Rowe

Prana Biotechnology BSC Presntation 20180107 FINAL

Post navigation

Prana Presents at Biotech Showcase

Prana receives Orphan Designation for PBT434 for treatment of MSA

Related Posts

Prana provides regulatory update for PBT2 for the treatment of Huntington disease

November 2, 2016

FDA End of Phase 2 Status Update

February 13, 2015

Prana receives $3 million R&D Tax Incentive Refund

December 19, 2017

Recent Posts

Quarterly Cash Flow Report
Alterity PBT434 Poster Presented at 2019 MDS Congress
Alterity presents clinical data on PBT434 at the 2019 MDS Congress
Alterity Therapeutics to Present at the Janney Healthcare Conference in New York
XBRL 30 June 2019 filed with the SEC

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Therapies
The Science
About us
Investors
News
Contact us

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065